ArticleOncogenesis2017
API5 confers cancer stem cell-like properties through the FGF2-NANOG axis.
Article in Oncogenesis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- The E2F1-HMGCR axis promotes ferroptosis resistance in immune refractory tumor cells.Nature communications · 2025Article
- Detection of pre-transition phases during biological development using single-sample network entropy (SNE).NPJ systems biology and applications · 2025Article
- An efficient epithelial-mesenchymal transition-related gene signature for predicting the survival of patients with lung adenocarcinoma.Translational cancer research · 2025Article
- Apoptosis Inhibitor 5: A Multifaceted Regulator of Cell Fate.Biomolecules · 2024Review
- Methionine consumption by cancer cells drives a progressive upregulation of PD-1 expression in CD4 T cells.Nature communications · 2023Article
- Article
- A NANOG-pERK reciprocal regulatory circuit regulates Nanog autoregulation and ERK signaling dynamics.EMBO reports · 2022Article
- Pan-Cancer Analysis Reveals the Prognostic Potential of the THAP9/THAP9-AS1 Sense-Antisense Gene Pair in Human Cancers.Non-coding RNA · 2022Article
- LGR6 activates the Wnt/β-catenin signaling pathway and forms a β-catenin/TCF7L2/LGR6 feedback loop in LGR6Oncogene · 2021Article
- DeSUMOylation of Apoptosis Inhibitor 5 bymBio · 2021Article
- Interplay between p300 and HDAC1 regulate acetylation and stability of Api5 to regulate cell proliferation.Scientific reports · 2021Article
- Article
- Immune evasion by cancer stem cells.Regenerative therapy · 2021Review
- Regulation of mRNA export through API5 and nuclear FGF2 interaction.Nucleic acids research · 2020Article
- FGF2: a novel druggable target for glioblastoma?Expert opinion on therapeutic targets · 2020Review
- Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis.Immune network · 2020Review
- HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors.Nature communications · 2020Article
- LINC00511 Promotes Osteosarcoma Tumorigenesis and Invasiveness through the miR-185-3p/E2F1 Axis.BioMed research international · 2020Article
- MicroRNA-497-5p inhibits proliferation and invasion of non-small cell lung cancer by regulating FGF2.Oncology letters · 2019Article
- Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune selection drives the evolution of tumor cells toward an immune-resistant and cancer stem cell (CSC)-like phenotype. We reported that apoptosis inhibitor-5 (API5) acts as an immune escape factor, which has a significant role in controlling immune resistance to antigen-specific T cells, but its functional association with CSC-like properties remains largely unknown. In this study, we demonstrated for the first time that API5 confers CSC-like properties, including NANOG expression, the frequency of CD44-positive cells and sphere-forming capacity. Critically, these CSC-like properties mediated by API5 are dependent on FGFR1 signaling, which is triggered by E2F1-dependent FGF2 expression. Furthermore, we uncovered the FGF2-NANOG molecular axis as a downstream component of API5 signaling that is conserved in cervical cancer patients. Finally, we found that the blockade of FGFR signaling is an effective strategy to control API5
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.